Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

Phase 1 Completed 42 enrolled Disc Medicine, Inc

RandomizedSequentialQuadruple-blindTreatment

Summary

This Phase 1 study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult healthy volunteers.

Timeline

Start: 2021-08-10
Primary completion: 2022-06-30
Completion: 2022-06-30

Publications

Novikov N, Buch A, Yang H, Andruk M, Liu G, Wu M, Howell H, MacDonald B, Savage W. First-in-Human Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of DISC-0974, an Anti-Hemojuvelin Antibody, in Healthy Participants. J Clin Pharmacol. 2024 Aug;64(8):953-962. doi: 10.1002/jcph.2432. Epub 2024 Mar 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DISC-0974	Monoclonal antibody	7 mg	Intravenous
Subject	DISC-0974	Monoclonal antibody	56 mg	Intravenous

Indications

No indication recorded.